During the past decade, A Premier Medical Research of Florida, LLC / ID # 752 conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 1 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 1 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "A Premier Medical Research of Florida, LLC / ID # 752" are "Endometriosis" (3 trials) and "Uterine Fibroids" (1 trials). Many other conditions were trialed in "A Premier Medical Research of Florida, LLC / ID # 752" in a lesser frequency.

Most popular intervention types in "A Premier Medical Research of Florida, LLC / ID # 752" are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "200 mg linzagolix tablet" (2 trials), "75 mg linzagolix tablet" (2 trials), "Add-back capsule (E2 1 mg / NETA 0.5 mg)" (2 trials), "Placebo" (2 trials) and "Placebo capsule to match Add-back capsule" (2 trials). Other intervention names were less common.

The vast majority of trials in "A Premier Medical Research of Florida, LLC / ID # 752" are 4 trials for "Female" genders.

Currently, there are NaN active trials in "A Premier Medical Research of Florida, LLC / ID # 752". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in A Premier Medical Research of Florida, LLC / ID # 752, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in A Premier Medical Research of Florida, LLC / ID # 752, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".